Clinical trials: Frailty
COVID-19
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom.
- Trial name
- NCT07090486
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 14,000 people
- Sponsor
- Pfizer
Frailty, Muscle Loss
A Randomized-Control Study of Gym Tonic's Community Based Strength Training Intervention.
Launched in April 2015 , Gym Tonic is the first of its kind cross-border exercise-as-medicine partnership between research institutions, business enterprises and service providers from Singapore and Finland.
- Conditions
- Frailty, Muscle Loss, Sarcopenia
- Trial name
- NCT04661618
- Testing
- Gym Tonic programme and Gym equipment
- Where
- Singapore
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- PulseSync Pte Ltd
Fraility, Risk of Falling
Physical Activity Monitoring in Frailty and Falling
BioSensics has developed a Physical Activity Monitoring System (PAMSys) that consists of a single wearable motion sensor that is worn on the torso.
- Trial name
- NCT01880229
- Where
- 2 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- BioSensics
Heart Failure
FRailty WAlking Patterns (FRAP) Study
The aim of this study is to evaluate sit-stand phases and gait speed detection using an externally worn Reveal LINQ (TM) compared to an external reference (3D accelerometer, and/or the Computer Assisted Rehabilitation Environment…
- Trial name
- FRAP (NCT02755129)
- Testing
- Walking Exercises-Six Minute Walk (6MW) Test, Walking Exercises-4 Meter Gait Speed (4MGS) Test, Walking Exercises-Five Times Sit to Stand (FTSTS) Test
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Medtronic BRC
Aging Frailty
Lomecel-B on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty
This is a phase I/II, randomized, blinded and placebo-controlled study to test the safety and efficacy of Lomecel-B for improving vaccine immune response.
- Trial name
- HERA (NCT02982915)
- Testing
- Longeveron Mesenchymal Stem Cells (LMSCs), Fluzone High Dose Vaccine
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- Longeveron Inc.
Sarcopenia, Frailty
BandPass: A Remote Monitoring System for Sarcopenia and Functional Decline Phase II Aim 4
This study evaluates a home-based strengthening program supported by the BandPass system, which includes a Bluetooth-enabled resistance exercise band, a mobile app that provides real-time feedback, and a clinician dashboard for…
- Trial name
- NCT07421648
- Testing
- BandPass System
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- SynchroHealth LLC
Frail Elderly Syndrome
Management of Frailty in Older Adults With Turmeric and Tulsi Supplements
The aim of this study is to determine the efficacy of turmeric and tulsi polyherbal formulation in the management of frailty in the elderly population.
- Trial name
- NCT03365310
- Testing
- C. longa, curcuminoids , Z. officianale, O. sanctum along with 200 ml of Milk, Standard of Care
- Where
- India
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Composite Interceptive Med Science
Aging Frailty
A Study to Evaluate Allogenic Bone-Marrow Mesenchymal Stromal Cell Product StromaForte in Aging Frailty Patients
This phase I/IIa study in frail patients is designed to assess the safety of intravenous human allogenic bone marrow-derived mesenchymal stromal cell product StromaForte by reporting the number of adverse events assessed by…
- Trial name
- NCT06063590
- Testing
- StromaForte
- Where
- United Arab Emirates
- Volunteers
- 12 people
- Sponsor
- Cellcolabs Clinical SPV Limited
Frail Elderly Syndrome
A Machine Learning Algorithm to Predict Health Clinical Situations in Primary Healthcare for Frail Older Adults.
Introduction: We developed a machine learning algorithm to predict the risk of emergency hospitalization within the new 7 to 14 days with a good predictive performance (AUC=0.85).
- Trial name
- NCT06013709
- Testing
- PRESAE CARE
- Volunteers
- 1,478 people
- Sponsor
- Presage
Frailty
AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
The purpose of this study is to look at the safety of treatment with stem cells in patients with Frailty.
- Trial name
- CRATUS (NCT02065245)
- Testing
- Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Longeveron Inc.
Frailty Syndrome
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the health of patients with human frailty syndrome.
- Trial name
- NCT01501461
- Testing
- Harvesting and implantation of stem cells
- Where
- Mexico
- Sponsor
- Ageless Regenerative Institute
Frailty
Safety Study of Intravenous MiraMSC in Older Adults With Mild to Moderate Frailty Syndrome
The purpose of this Phase I, open-label study is to evaluate the safety and tolerability of intravenous MiraMSC-FS-001 in older adults with mild to moderate frailty syndrome.
- Trial name
- NCT07705464
- Testing
- MiraMSC-FS-001
- Volunteers
- 12 people
- Sponsor
- Miracle Biomedical Co., Ltd.
Age-related Muscle Decline
CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy
This Phase 1/2a, open-label, non-randomized study is designed to evaluate the safety and tolerability of intramuscular AAV9-Follistatin gene therapy administered either as monotherapy or in combination with a VEGF-encoding…
- Trial name
- CALM-AF-AI (NCT07443826)
- Testing
- AAV9-Follistatin gene therapy, VEGF Plasmid
- Where
- Honduras
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Unlimited Biotechnology LLC
Frailty
A Study of Human Allogeneic Bone-marrow-derived Mesenchymal Stromal Cell Product (StromaForte) in Patients With Aging Frailty
The goal of this phase I/II clinical trial is to evaluate the safety and tolerability of intravenous infusion of human allogeneic bone-marrow-derived mesenchymal stromal cell product StromaForte in patients with aging frailty.
- Trial name
- NCT06070532
- Testing
- Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product (StromaForte)
- Where
- The Bahamas
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cellcolabs Clinical LTD.
Frailty, Aging
Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy in Humans
This study examines the safety and effects of an injectable plasmid gene therapy. Plasmids are circular pieces of DNA which have been widely studied as a non-permanent \& non-heritable method for transferring genes and inducing…
- Trial name
- NCT06411366
- Testing
- Follistatin plasmid
- Where
- Honduras
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Minicircle
Pathologic Processes
Mesenchymal Stem Cells for Frailty Syndrome
This Phase I/II study is designed to evaluate the efficacy and safety of UMC119-06-05, an allogeneic umbilical cord mesenchymal stem cells, in older adults with frailty syndrome.
- Trial name
- NCT06501066
- Testing
- umbilical cord mesenchymal stem cells
- Where
- 2 sites in Taiwan
- Volunteers
- 66 people
- Sponsor
- Meribank Biotech Co., Ltd.